Biomed Industries Announces Phase 3 Trials of NA-931 Targeting Durable Weight Loss & Lean-Mass Preservation at JPM Week

Biomed Industries, Inc. Announces Two NA-931 Phase 3 Trials, Targeting Durable Weight Loss & Lean-Mass Preservation ...

What are GLP-3s? Meet the new generation of weight-loss drugs with three key ingredients

Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the improvement of other conditions in longer studies.
FierceBiotech

Viking's obesity med set to charge into phase 3, with $300M earmarked for clinical program

Viking Therapeutics will launch a longship into phase 3 for the obesity drug VK2735 sooner than expected, with a clinical program expected to top $300 million. The biotech—which was launched into the ...

Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain

Engineered to Deliver Potent Pain Relief with Built-In Abuse Protection ~ SAN DIEGO, CA / ACCESS Newswire / January 28, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a ...
Nasdaq

First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non ...

PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...
FierceBiotech

Immunovant won't seek approval for autoimmune drug despite phase 3 win

A phase 3 trial of Immunovant’s FcRn inhibitor batoclimab has hit its primary endpoint. But, having made a second-generation molecule its lead candidate last year, the biotech isn’t currently planning ...